ABOUT US

Overview

Life technology innovation
Global biotechnology experts joined together to realize a single dream.
That dream is for S.Biomedics to lead the development of complete and safe biotechnology innovations for the health of human beings. The world’s first domestically researched and developed autologous fibroblast treatment, S.Biomedic’s technology is both innovative and refined.
As the leading specialized cell therapy company, S.biomedics will provide the best in biotechnology to mankind.

Core value

Respect

A human life company

Responsibility

An honest and socially responsible company

innovation

A creative and innovative company

Leadership

A leading cell therapy technology company

history

2017.08
KGMP production facility expansion
2017.04
Completed Clinical Phase 2 of Immune Cell Therapy
2017.03
Signed technology transfer agreement with domestic Y university for secretome stroke treatment
2016.12
Establishment of sales corporation S.thepharm.Co., Ltd.
2016.12
Transfer of patent for embryonic stem cell therapy
2016.07
Transfer of patent and technology for immune cell therapy
2016.04
Signed MOA with Indian U company regarding CureSkin India market
2016.04
K Joint development with K Laboratory on 3D micro-biotechnology technology
2015.12
Started development of embryonic stem cell treatment for spinal cord injury with Professor Kim Dong-wook of Yonsei University and Binex
2014.11
Joint development of mesenchymal therapeutic agent with Hospital A in Korea
2013.05
Launched joint development of immunotherapy (TK-Cell) with BINEX
2013.05
Launched joint development of BINEX immunotherapy (TK-Cell)
2012.03
Signed cell therapy strategic alliance with BINEX
2011.02
Launch of autologous fibroblast treatment (cure skin)
2010.05
KGMP qualified company
2009.10
Attained pharmaceutical manufacturing certificate
2009.09
Completion of animal testing center
2009.06
Started research of retinal cell therapy with Tsinghua University, Beijing, China
2009.05
Completed clinical trial of autologous skin fibroblast treatment
2008.04
Started clinical trial of autologous skin fibroblast treatment with Korea University Hospital
2008.01
Completed preclinical testing of corneal cell treatment agent (toxicity)
2007.12
Completion of preclinical examination of autologous skin fibroblast treatment
2007.10
Acquired venture company certification
2007.04
Accreditation of research institute
2007.04
Completed KGMP facility
2006.11
completed transfer of autologous skin fibroblast technology
2006.06
Establishment of R&D facilities
2005.10
Incorporation of S.biomedics.Co.Ltd

team

Sae Il Kang

Chemchina Chemical Group, International Business department
Ecole Hoteliere de Lausanne

Dr. Dong Wook Kim

Yonsei University Medical School Professor (Present) Head of Stem Cell-based New Drug Development Research Group Head of Cellular Applications Research department (Past)
Genetic Engineering BS, Korea University
Biotechnology PhD, Tokyo University

Han Chang Hee

HanMi Pharm CFO (Past)
Business Administration MS, Seogang University

Sang Heon Kim

University of Science & Technology Professor
(Present) Senior researcher, Korea Institute of Science and Technology
Biotechnology phD, Tokyo Institute of Technology

Dr. Myung soo Jo

Jaeil Pharm Central R&D Institute (Past)
Planning Committee of New Drug/ Stem Cell division (Present) Advisory Committee on Stem Cell Line Registration of Disease Control division (Present)
Life sciences PhD, Ajou University

Bum Soo Lee

Dental DDS, Columbia University College of Dental Medicine
Molecular biology bachelor’s degree, Haverford College

Jae Hyuk Lee

BNC Korea Sales manager (Past)
Hugel Pharma Sales manager (Past)
Materials Engineering BS, Soonchunhyang University

Jong Wan Kim

SK Chemical corporation (Past)
Molecular Biology MS, Korea University

Won geun Kim

Deputy chairman, Korea Development Bank (past)
Econoimcs Master’s degree, Yonsei University graduate school of business

Map to Head Office

Map to Facility

location

Head Office

28 26, Seongsui, Seongdong-gu, Seoul, Korea 4th Floor


Medical Device Facility

Unit #1111, 19, Ojeongongeop-gil, Uiwang-si, Gyeonggi-do, Republic of Korea